G
Gad Getz
Researcher at Broad Institute
Publications - 627
Citations - 309042
Gad Getz is an academic researcher from Broad Institute. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 189, co-authored 520 publications receiving 247560 citations. Previous affiliations of Gad Getz include University of Colorado Denver & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Oksana Zavidij,Oksana Zavidij,Nicholas J. Haradhvala,Nicholas J. Haradhvala,Tarek H. Mouhieddine,Tarek H. Mouhieddine,Romanos Sklavenitis-Pistofidis,Romanos Sklavenitis-Pistofidis,Songjie Cai,Songjie Cai,Mairead Reidy,Mairead Reidy,Mahshid Rahmat,Mahshid Rahmat,Abdallah Flaifel,Abdallah Flaifel,Benjamin Ferland,Nang K. Su,Michael P. Agius,Michael P. Agius,Jihye Park,Jihye Park,Salomon Manier,Mark Bustoros,Mark Bustoros,Daisy Huynh,Marzia Capelletti,Marzia Capelletti,Brianna Berrios,Chia Jen Liu,Meng Xiao He,Meng Xiao He,Esteban Braggio,Rafael Fonseca,Yosef E. Maruvka,Jennifer L. Guerriero,Melissa Goldman,Melissa Goldman,Eliezer M. Van Allen,Eliezer M. Van Allen,Steven A. McCarroll,Steven A. McCarroll,Jamil Azzi,Jamil Azzi,Gad Getz,Gad Getz,Irene M. Ghobrial,Irene M. Ghobrial +47 more
TL;DR: Using single-cell RNA sequencing of bone marrow cells from precursor stages, MGUS and smoldering myeloma (SMM), to full-blown MM alongside healthy donors, this work demonstrates early immune changes during patient progression.
Journal ArticleDOI
Clonal evolution in hematological malignancies and therapeutic implications.
TL;DR: These studies reveal the complex evolutionary trajectories occurring across individual hematological malignancies and suggest that while clonal evolution may contribute to resistance to therapy, treatment may also hasten the evolutionary process.
Journal ArticleDOI
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma
Rachel G. Liao,Joonil Jung,Jeremy H. Tchaicha,Matthew D. Wilkerson,Andrey Sivachenko,Ellen M. Beauchamp,Qingsong Liu,Trevor J. Pugh,Chandra Sekhar Pedamallu,D. Neil Hayes,Nathanael S. Gray,Gad Getz,Kwok-Kin Wong,Robert I. Haddad,Matthew Meyerson,Peter S. Hammerman +15 more
TL;DR: The oncogenic nature of mutations observed in FGFR2 and FGFR3, each of which are observed in 3% of samples, are described, for a mutation rate of 6% across both genes.
Journal ArticleDOI
PRADA: Pipeline for RNA sequencing Data Analysis
Wandaliz Torres-Garcia,Siyuan Zheng,Andrey Sivachenko,Rahulsimham Vegesna,Qianghu Wang,Rong Yao,Michael F. Berger,John N. Weinstein,Gad Getz,Roel G.W. Verhaak +9 more
TL;DR: PRADA is a flexible, modular and highly scalable software platform that provides many different types of information available by multifaceted analysis starting from raw paired-end RNA-seq data: gene expression levels, quality metrics, detection of unsupervised and supervised fusion transcripts, Detection of intragenic fusion variants, homology scores and fusion frame classification.
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim,Craig H. Mermel,Craig H. Mermel,Dale Porter,Guo Wei,Soumya Raychaudhuri,Soumya Raychaudhuri,Jerry Donovan,Jordi Barretina,Jordi Barretina,Jesse S. Boehm,Jennifer Dobson,Jennifer Dobson,Mitsuyoshi Urashima,Kevin T. Mc Henry,Reid M. Pinchback,Azra H. Ligon,Yoon Jae Cho,Leila Haery,Leila Haery,Heidi Greulich,Michael R. Reich,Wendy Winckler,Michael S. Lawrence,Barbara A. Weir,Barbara A. Weir,Kumiko E. Tanaka,Kumiko E. Tanaka,Derek Y. Chiang,Derek Y. Chiang,Derek Y. Chiang,Adam J. Bass,Adam J. Bass,Adam J. Bass,Alice Loo,Carter Hoffman,Carter Hoffman,John R. Prensner,John R. Prensner,Ted Liefeld,Qing Gao,Derek Yecies,Sabina Signoretti,Sabina Signoretti,Elizabeth A. Maher,Frederic J. Kaye,Hidefumi Sasaki,Joel E. Tepper,Jonathan A. Fletcher,Josep Tabernero,José Baselga,Ming-Sound Tsao,Francesca Demichelis,Mark A. Rubin,Pasi A. Jänne,Pasi A. Jänne,Mark J. Daly,Mark J. Daly,Carmelo Nucera,Ross L. Levine,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert,Stacey Gabriel,Anil K. Rustgi,Cristina R. Antonescu,Marc Ladanyi,Anthony Letai,Levi A. Garraway,Levi A. Garraway,Massimo Loda,Massimo Loda,David G. Beer,Lawrence D. True,Aikou Okamoto,Scott L. Pomeroy,Samuel Singer,Todd R. Golub,Todd R. Golub,Todd R. Golub,Eric S. Lander,Eric S. Lander,Eric S. Lander,Gad Getz,William R. Sellers,Matthew Meyerson,Matthew Meyerson +86 more
TL;DR: In this paper, the authors identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions.